Campylobacter jejuni extracellular vesicles harboring cytolethal distending toxin bind host cell glycans and induce cell cycle arrest in host cells.

Autor:	Le LHM; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Victoria, Australia.; Department of Microbiology, Biomedicine Discovery Institute, Monash University, Victoria, Australia., Elgamoudi B; Institute for Glycomics, Griffith University, Gold Coast, Queensland, Australia., Colon N; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Victoria, Australia., Cramond A; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Victoria, Australia., Poly F; Enteric Diseases Department, Naval Medical Research Centre, Silver Spring, Maryland, USA., Ying L; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Victoria, Australia.; Department of Molecular and Translational Sciences, Monash University, Victoria, Australia., Korolik V; Institute for Glycomics, Griffith University, Gold Coast, Queensland, Australia., Ferrero RL; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Victoria, Australia.; Department of Microbiology, Biomedicine Discovery Institute, Monash University, Victoria, Australia.; Department of Molecular and Translational Sciences, Monash University, Victoria, Australia.
Jazyk:	angličtina
Zdroj:	Microbiology spectrum [Microbiol Spectr] 2024 Mar 05; Vol. 12 (3), pp. e0323223. Date of Electronic Publication: 2024 Feb 06.
DOI:	10.1128/spectrum.03232-23
Abstrakt:	Cytolethal distending toxins (CDTs) are released by Gram-negative pathogens into the extracellular medium as free toxin or associated with extracellular vesicles (EVs), commonly known as outer membrane vesicles (OMVs). CDT production by the gastrointestinal pathogen Campylobacter jejuni has been implicated in colorectal tumorigenesis. Despite CDT being a major virulence factor for C. jejuni , little is known about the EV-associated form of this toxin. To address this point, C. jejuni mutants lacking each of the three CDT subunits (A, B, and C) were generated. C. jejuni cdtA, cdtB, and cdtC bacteria released EVs in similar numbers and sizes to wild-type bacteria, ranging from 5 to 530 nm (mean ± SEM = 118 ±6.9 nm). As the CdtAC subunits mediate toxin binding to host cells, we performed "surface shearing" experiments, in which EVs were treated with proteinase K and incubated with host cells. These experiments indicated that CDT subunits are internal to EVs and that surface proteins are probably not involved in EV-host cell interactions. Furthermore, glycan array studies demonstrated that EVs bind complex host cell glycans and share receptor binding specificities with C. jejuni bacteria for fucosyl GM1 ganglioside, P1 blood group antigen, sialyl, and sulfated Lewis x . Finally, we show that EVs from C. jejuni WT but not mutant bacteria induce cell cycle arrest in epithelial cells. In conclusion, we propose that EVs are an important mechanism for CDT release by C. jejuni and are likely to play a significant role in toxin delivery to host cells. Importance: Campylobacter jejuni is the leading cause of foodborne gastroenteritis in humans worldwide and a significant cause of childhood mortality due to diarrheal disease in developing countries. A major factor by which C. jejuni causes disease is a toxin, called cytolethal distending toxin (CDT). The biology of this toxin, however, is poorly understood. In this study, we report that C. jejuni CDT is protected within membrane blebs, known as extracellular vesicles (EVs), released by the bacterium. We showed that proteins on the surfaces of EVs are not required for EV uptake by host cells. Furthermore, we identified several sugar receptors that may be required for EV binding to host cells. By studying the EV-associated form of C. jejuni CDT, we will gain a greater understanding of how C. jejuni intoxicates host cells and how EV-associated CDT may be used in various therapeutic applications, including as anti-tumor therapies. Competing Interests: The authors declare no conflict of interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu